Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

USP Negative Ephedra Monograph To Follow FDA Final Action

This article was originally published in The Tan Sheet

Executive Summary

The United States Pharmacopeia plans to create a negative monograph for ephedra following FDA action on the dietary supplement ingredient, CEO Jerome Halperin said at a meeting of the USP Ad Hoc Panel on Botanicals in Rockville, Md. Nov. 8.

You may also be interested in...



Chaparral AER Data Resembles Kava Reports, CRN’s Cardellina Says

Adverse event reports on chaparral have certain parallels with those that have been filed for kava, according to Council for Responsible Nutrition VP-Botanical Science & Regulatory Affairs John Cardellina, PhD

Chaparral AER Data Resembles Kava Reports, CRN’s Cardellina Says

Adverse event reports on chaparral have certain parallels with those that have been filed for kava, according to Council for Responsible Nutrition VP-Botanical Science & Regulatory Affairs John Cardellina, PhD

Chaparral AER Data Resembles Kava Reports, CRN’s Cardellina Says

Adverse event reports on chaparral have certain parallels with those that have been filed for kava, according to Council for Responsible Nutrition VP-Botanical Science & Regulatory Affairs John Cardellina, PhD

Related Content

Topics

UsernamePublicRestriction

Register

PS090575

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel